CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 116 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $94,401 | -25.3% | 73,179 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $126,451 | +14.4% | 73,179 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $110,500 | +76.1% | 73,179 | -12.0% | 0.00% | -66.7% |
| Q4 2022 | $62,753 | -48.1% | 83,179 | 0.0% | 0.00% | +200.0% |
| Q3 2022 | $121,000 | -21.9% | 83,179 | -1.2% | 0.00% | 0.0% |
| Q2 2022 | $155,000 | -30.8% | 84,179 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $224,000 | -38.6% | 84,179 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $365,000 | -42.4% | 84,179 | -32.3% | 0.00% | -25.0% |
| Q3 2021 | $634,000 | +18.9% | 124,356 | +47.7% | 0.00% | -20.0% |
| Q2 2021 | $533,000 | -19.0% | 84,179 | -1.2% | 0.01% | -16.7% |
| Q1 2021 | $658,000 | +15.2% | 85,179 | -2.3% | 0.01% | 0.0% |
| Q4 2020 | $571,000 | -29.9% | 87,175 | -21.6% | 0.01% | -45.5% |
| Q3 2020 | $815,000 | -26.5% | 111,178 | -16.5% | 0.01% | -26.7% |
| Q2 2020 | $1,109,000 | +2.4% | 133,177 | -5.7% | 0.02% | -25.0% |
| Q1 2020 | $1,083,000 | -8.3% | 141,177 | -0.7% | 0.02% | +11.1% |
| Q4 2019 | $1,181,000 | +19.2% | 142,177 | -0.1% | 0.02% | +20.0% |
| Q3 2019 | $991,000 | -40.0% | 142,270 | -3.4% | 0.02% | -50.0% |
| Q2 2019 | $1,652,000 | -29.3% | 147,270 | -9.7% | 0.03% | -34.8% |
| Q1 2019 | $2,337,000 | -5.2% | 163,177 | -0.1% | 0.05% | -22.0% |
| Q4 2018 | $2,465,000 | -18.4% | 163,260 | +0.1% | 0.06% | -4.8% |
| Q3 2018 | $3,019,000 | -21.4% | 163,177 | -1.2% | 0.06% | -1.6% |
| Q2 2018 | $3,843,000 | -8.4% | 165,231 | -10.8% | 0.06% | -64.4% |
| Q4 2017 | $4,194,000 | +14.6% | 185,187 | 0.0% | 0.18% | +94.5% |
| Q3 2017 | $3,661,000 | +123.2% | 185,187 | +85.2% | 0.09% | +106.8% |
| Q2 2017 | $1,640,000 | -51.1% | 100,000 | -49.3% | 0.04% | -53.2% |
| Q1 2017 | $3,356,000 | +42.4% | 197,177 | -7.5% | 0.09% | +22.1% |
| Q4 2016 | $2,357,000 | -28.3% | 213,177 | +0.5% | 0.08% | -42.5% |
| Q3 2016 | $3,287,000 | +47.3% | 212,189 | -3.4% | 0.13% | +48.9% |
| Q2 2016 | $2,232,000 | – | 219,689 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |